Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience

MLA

Alexandra C Villani, et al. “Cost of Inpatient Admissions for Immune-Related Adverse Effects from Immune Checkpoint Inhibitor Therapy: A Single Center Experience.” Journal of Clinical Oncology, vol. 36, May 2018, p. 3060. EBSCOhost, https://doi.org/10.1200/jco.2018.36.15_suppl.3060.

APA

Alexandra C Villani, Molly Thomas, Amanda C. Guidon, Justine V. Cohen, Jacqueline N. Chu, Rebecca Karp Leaf, Alexander T. Faje, Mazen Nasrallah, Kerry L. Reynolds, Ryan J. Sullivan, Jin G. Choi, Steven T. Chen, Ian M. Allen, Sassan Ostvar, Meghan E. Sise, Aditya Bardia, Tomas G. Neilan, Sara R. Schoenfeld, Chin Hur, & Michael Dougan. (2018). Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience. Journal of Clinical Oncology, 36, 3060. https://doi.org/10.1200/jco.2018.36.15_suppl.3060

Chicago

Alexandra C Villani, Molly Thomas, Amanda C. Guidon, Justine V. Cohen, Jacqueline N. Chu, Rebecca Karp Leaf, Alexander T. Faje, et al. 2018. “Cost of Inpatient Admissions for Immune-Related Adverse Effects from Immune Checkpoint Inhibitor Therapy: A Single Center Experience.” Journal of Clinical Oncology 36 (May): 3060. doi:10.1200/jco.2018.36.15_suppl.3060.